Arca biopharma cardiovascular news

Arca restructured and reduced headcount by about 40 (56%) to 31 as the biotech seeks strategic alternatives to commercialize its Gencaro bucindolol, including a co-marketing deal, a marketing partner or sale of the compound. The non-selective beta blocker is under FDA review to treat chronic heart failure and prevent myocardial infarction (MI) in patients with symptomatic chronic heart failure and had a PDUFA date of May 31. The company said it is seeking alternatives to save the expense of establishing a sales force. ...